Objective:To investigate the effect of adjuvant therapy on the treatment of stage Ⅱ pancreatic carcinomas.
Methods:The clinical data of 139 patients with stage Ⅱ pancreatic carcinoma were analyzed tetrospectively.
Results:The overall 1, 3 and 5-year cumulative survival rate of 139 patients was 40%, 6% and 3% respectively, and the median survival time (MST) was 279 days. The MST was  390 days for the radical resection group, 270 days for the bypass operation and laparotomy group, and 132 days for the non-surgical group;  and 399 days for those with adjuvant therapy, 210 days for those without adjuvant therapy; The adjuvant therapy did not significantly prolong the survival time nor decrease the liver metastasis rate in the patients with stage Ⅱ carcinoma undergoing radical resection (P＞0.05). However, in the patients undergoing bypass operation, laparotomy or non-surgiery, the adjuvant therapy improved the survival significantly (P＜0.05), but the survival rate was not significantly different between systemic venous chemotherapy, radiation therapy, interventional therapy and combination therapy (P＞0.05); and was also not significant difference between gemcitabine (GEM) regimen and 5-fluorouracil regimen (P＞0.05), or between GEM monotherapy and GEM combined with platinum/capecitabine (P＞0.05).
Conclusions:The proper adjuvant therapy can be suggested for the patients after radical resection for stage Ⅱ pancreatic carcinoma according to patient′s condition. Chemotherapy combined with radiation should be applied aggressively for the patients whose cancer was not radically resected. The clinical efficacy of GEM combined with platinum/capecitabine is relatively better than GEM alone.